US Patent 8,815,934 Landscape: Scope and Claim Coverage for Oral Conjugated Estrogen + Indole-Phenol Conjugate in Post-Menopausal Syndrome

US Patent 8,815,934 is directed to an oral solid pharmaceutical composition for post-menopausal syndrome that combines: (i) conjugated estrogens at 0.3 mg to 2.5 mg and (ii) a specific indole-phenol substituted benzyl-ether azepane compound (the claim recites 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt) at 1 mg to 150 mg, in a pharmaceutically acceptable carrier/excipient. The claim as written is a product-composition claim with tight drug identity constraints and range-based dose limitations.

What the independent claim covers (plain-English scope)

Claim 1 covers any US “tablet or capsule” product that meets all elements:

Dosage form: an oral dosage presented as a tablet or capsule.
Indication: “for the treatment of post-menopausal syndrome.”
Combination drug identity:
- Conjugated estrogens amount 0.3 mg to 2.5 mg
- AND the specific indole-phenol compound (or salt) amount 1 mg to 150 mg
Formulation: a pharmaceutically acceptable carrier/excipient.

What the independent claim does not cover (implied exclusions from the claim language)

Non-oral formulations (e.g., transdermal gels, injectables).
Oral solutions/suspensions unless they are construed as “tablet or capsule.”
Compositions where the estrogen is not “conjugated estrogens” as recited.
Combinations using a different amount range outside the stated windows.
Combinations using a different active than the specific indole-phenol recited (even if pharmacologically similar), except via “pharmaceutically acceptable salt” of the recited compound.
Products that use the recited actives but are marketed or labeled for a different indication, where “for the treatment of post-menopausal syndrome” is treated as a required element under the doctrine of infringement.

How broad is the scope of claim 1 for US 8,815,934?

Claim 1 is broad on excipients and narrow on active identity and dose. It is not limited to a particular manufacturing method, release profile (immediate vs extended release), or specific excipient list in the claim language you provided. That said, the claim still requires:

a specific chemical entity (or salt) for the non-estrogen component
a specific chemical class for estrogen (conjugated estrogens, not “estrogen” generically)
dose ranges for both components
tablet or capsule oral form

Element-by-element claim map (infringement relevance)

Claim element	Written requirement	Practical infringement gate
Oral dosage form	tablet or capsule	A competitor must make and sell a tablet/capsule product in the US
Indication	treatment of post-menopausal syndrome	A competitor product must be used or intended for that indication in a way that satisfies claim construction
Conjugated estrogens dose	0.3 mg to 2.5 mg	Formulations outside that window avoid literal coverage
Indole-phenol compound dose	1 mg to 150 mg	Most design-around attempts focus here
Salt coverage	pharmaceutically acceptable salt	Competitors can still infringe if they use a salt form within scope
Carrier/excipient	pharmaceutically acceptable	Essentially any conventional solid oral formulation is included

What is the key drug-identity bottleneck in US 8,815,934 claims?

The non-estrogen component is a highly specific chemical in the claim:

1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol (or pharmaceutically acceptable salt).

That specificity functions as the main limiting factor. A generic or biosimilar-style challenge is not directly applicable here because this is not a biologic and the active is chemically defined. Design-around efforts usually fall into one of three buckets:

Change the non-estrogen molecule to a structurally different compound.
Use the same molecule at a dose outside 1 mg to 150 mg.
Avoid “tablet or capsule” by using other oral formats.
Use “estrogens” that are not “conjugated estrogens.” (e.g., estradiol only products, ester mixtures not matching the defined term, depending on construction.)

How do the dosage ranges constrain infringement risk for generic or reformulated products?

Claim 1 uses two quantitative windows:

Conjugated estrogens: about 0.3 mg to about 2.5 mg
Non-estrogen indole-phenol: about 1 mg to about 150 mg

Range-based attack paths

Low-dose estrogen avoidance: If a competitor reformulates to below about 0.3 mg per unit dose.
High-dose estrogen avoidance: If reformulated above about 2.5 mg.
Low-dose indole-phenol avoidance: Below about 1 mg.
High-dose indole-phenol avoidance: Above about 150 mg.

Range language “about” can widen the factual infringement surface. But from a patent landscape viewpoint, range limits still create a measurable design-around space.

Which product formats are covered: tablets vs capsules vs other oral dosage forms?

The claim is explicitly limited to “tablet or capsule.” This matters in two ways:

A competitor that sells an oral solution, suspension, oral film, chewable, powder-in-sachet, or other non-tablet/capsule solid oral format is outside the claim’s literal text.
Even where courts use broad interpretations for “tablet” or “capsule,” most nonstandard forms create an initial noninfringement argument.

If US 8,815,934 is asserted against an IMMEDIATE-RELEASE tablet/capsule, claim 1 is directly implicated. If asserted against modified-release versions, the claim still covers the product type unless other dependent claims narrow release characteristics.

What patents typically sit around US 8,815,934: formulation, salt, method-of-use, and process?

Without the patent family text and dependent claims, the only safe statement is based on the independent claim you provided: US 8,815,934 at least covers a combination composition. In US ester/estrogen-combination patent families, the surrounding estate frequently includes:

Dependent composition claims specifying:
- unit strength targets (e.g., exact mg amounts)
- preferred excipient systems
- particle size, compression parameters, coating weights
Salt claims covering multiple pharmaceutically acceptable salts
Method-of-treatment claims (often aligned to “post-menopausal syndrome”)
Manufacturing/process claims for preparing the composition
Embodiments tied to delivery such as immediate vs extended release

These adjacent claim types are common in combination drug filings, but the only defensible coverage statement from your claim text is that claim 1 is a composition claim and that it requires the specific active identity and ranges.

How strong is the patent estate for a combination drug claim like this?

From claim 1 alone, strength is driven by three factors:

Claim specificity on the non-estrogen active
- This reduces the number of plausible literal infringements unless competitors copy the same molecule (or its salt).
Dose ranges
- Enables partial design-around by dose window changes.
Dosage form limitation
- Tablet/capsule limitation blocks many reformulation pathways.

Strength against generic “entry” depends on whether a follow-on product uses the same actives at overlapping doses in tablet/capsule format. If the market expects a reformulation with different strengths or a different oral form, risk can be materially reduced even if the same molecule is used.

What is the competitive landscape implication of this specific combination claim?

A valid reading of claim 1 implies that competitive products that target post-menopausal syndrome using:

conjugated estrogens plus
the same indole-phenol entity (or salt)
in tablet or capsule form within overlapping dose ranges are at high risk of infringement if asserted.

Competitors that instead:

use other estrogen forms (not “conjugated estrogens”)
use different active second components
or reformulate outside the mg windows
are at lower risk of literal infringement based on claim 1.

How do FDA regulatory status and Orange Book linkage typically affect claim 1 enforcement?

For composition patents on FDA-approved drugs, the usual enforcement pathway is via Orange Book listing and/or patent-owner enforcement against applicants that reference the NDA. But the provided record does not include:

whether US 8,815,934 is listed in the Orange Book
whether it is tied to an NDA, an ANDA, or a 505(b)(2)
whether any Paragraph IV certifications are filed

So the enforceability mechanics cannot be stated from the claim text alone. What can be stated from claim structure is that it is the kind of product-composition claim that often becomes an Orange Book-listed “drug substance” or “drug product” patent, subject to application-specific facts.

What Paragraph IV challenge risks exist for products overlapping this claim?

If an ANDA/505(b)(2) applicant files a certification tied to an Orange Book-listed patent of this type, risk depends on:

whether the applicant’s product includes the same indole-phenol active (or salt),
whether it uses conjugated estrogens (not just “estrogen”),
and whether the tablet/capsule unit strengths overlap 0.3–2.5 mg and 1–150 mg ranges.

A Paragraph IV opponent can also attempt invalidity arguments (anticipation/obviousness) if prior art discloses the same composition. The claim’s combination specificity increases the relevance of prior art that already teaches both actives together at claimed ranges and dosage forms.

How does US 8,815,934 compare with typical post-menopausal syndrome composition patents?

Relative to broad hormone replacement therapy patents that claim estrogen class compositions, claim 1 is narrower due to the:

specific chemical second active identity, and
explicit unit-dose mg ranges, and
tablet/capsule limitation.

Relative to method-of-use claims alone, it is a direct product claim, which can be easier to map to an accused product’s formulation and labeling evidence.

Key claim scope summary table for US 8,815,934

Category	Claim 1 requirement	Practical implication for infringement/design-around
Dosage form	oral tablet or capsule	Avoid non-tablet/capsule oral delivery
Indication	“for the treatment of post-menopausal syndrome”	Product intended for that indication is needed
Estrogen component	conjugated estrogens 0.3 mg–2.5 mg	Dose-window switching can reduce risk
Second component	specific indole-phenol compound (or salt) 1 mg–150 mg	Copying the exact molecule is a prerequisite for literal overlap
Formulation layer	pharmaceutically acceptable carrier/excipient	Standard solid formulation strategies likely fall within scope

Key Takeaways

US 8,815,934 claim 1 is a narrow composition claim anchored to a specific indole-phenol active plus conjugated estrogens at defined mg ranges.
Highest infringement exposure is for tablet/capsule products delivering both actives at overlapping doses for post-menopausal syndrome.
Most credible design-around levers are:
- shifting unit-dose amounts to fall outside 0.3–2.5 mg (conjugated estrogens) or 1–150 mg (indole-phenol),
- switching away from tablet/capsule oral format,
- or changing the second active identity away from the claimed indole-phenol (or salt).
Patent landscape breadth beyond claim 1 (dependent claims, family members, salts, methods, process) cannot be concluded from the single claim text provided, but the independent claim establishes the core commercial IP boundary: combination oral solid composition in that dosing envelope.

FAQs

1) Does US 8,815,934 cover extended-release tablets or only immediate-release?
Claim 1 requires only “tablet or capsule.” Without dependent-claim release limitations in the provided text, claim 1’s literal scope covers tablet/capsule formats regardless of release kinetics.

2) Can a competitor avoid infringement by using estradiol instead of conjugated estrogens?
Literal scope requires “conjugated estrogens.” Substituting a different estrogen substance can avoid the “conjugated estrogens” element depending on claim construction.

3) Is a salt form of the indole-phenol covered?
Yes. Claim 1 includes “a pharmaceutically acceptable salt thereof.”

4) What happens if a tablet’s unit dose slightly exceeds 2.5 mg conjugated estrogens?
Claim 1 is “about 0.3 mg to about 2.5 mg.” Avoidance depends on how “about” is construed and on the exact formulation and evidence of equivalence.

5) Are oral tablets/capsules the only dosage forms at risk?
For literal infringement of claim 1, the risk centers on tablet or capsule products. Other oral formats are not covered by the literal claim language.

References

US Patent 8,815,934 (claim 1 as provided by user prompt).

Details for Patent: 8,815,934

Summary for Patent: 8,815,934